CB 2679d/ISU304 has demonstrated significant advancements in the treatment of severe hemophilia B, being approximately 22 times more potent than the current standard therapy, BeneFIX®. This was measured by activity levels using a one-stage clotting assay. Additionally, CB 2679d showed a longer average circulation time of 34 hours compared to BeneFIX's 25 hours.
These findings are part of the ongoing Phase 1/2 proof-of-concept clinical trial conducted by Catalyst Biosciences, Inc., in collaboration with ISU Abxis, at three centers in South Korea. The trial aims to document the subcutaneous bioavailability and clotting ability of CB 2679d, with interim, top-line results expected by the end of 2017 and complete trial results anticipated in early 2018.
Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer, expressed excitement over the higher potency and improved pharmacokinetics of CB 2679d demonstrated in this clinical trial. He believes that CB 2679d will offer advantages over currently approved intravenous prophylactic treatments, which are known to have prolonged periods of low activity levels with an increased risk of spontaneous bleeding.
Hemophilia B is a rare but serious bleeding disorder resulting from a deficiency of a protein required for normal blood coagulation. Individuals with hemophilia B suffer from spontaneous bleeding episodes and prolonged bleeding times upon injury. CB 2679d is being evaluated as a potential subcutaneous prophylactic treatment for individuals with this condition, offering a more convenient and effective treatment option.
Catalyst Biosciences is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, particularly in the field of hemostasis. This includes the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia.
